Traws Pharma (TRAW) Other Non Operating Income (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Other Non Operating Income of -$2000.0 for Q1 2026, down 101.11% year-over-year from $180000.0 in Q1 2025, and down 114.29% quarter-over-quarter from $14000.0 in Q4 2025.
Traws Pharma (TRAW) Other Non Operating Income (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Other Non Operating Income for 15 consecutive years, with -$2000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 101.11% year-over-year to -$2000.0; the TTM figure through Mar 2026 stood at $296000.0 (up 23.33% YoY), while the FY2025 annual figure was $478000.0, up 65.4% from the prior year.
- Other Non Operating Income eased to -$2000.0 in Q1 2026 per TRAW's latest filing, from $14000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $362000.0 in Q1 2023 and bottomed at -$206000.0 in Q4 2024.
- Historically, Other Non Operating Income has averaged $163411.8 across 5 years, with a median of $188000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non Operating Income surged 31500.0% — and 2024, when it tumbled 174.1%.
- Traws Pharma's Other Non Operating Income stood at $314000.0 in 2022, then retreated by 11.46% to $278000.0 in 2023, then sank by 174.1% to -$206000.0 in 2024, then surged by 106.8% to $14000.0 in 2025, then slumped by 114.29% to -$2000.0 in 2026.
- Business Quant data shows TRAW's Other Non Operating Income at -$2000.0 in Q1 2026, $14000.0 in Q4 2025, and $96000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 96,000.00 |
| Jun 30, 2025 | 188,000.00 |
| Mar 31, 2025 | 180,000.00 |
| Dec 31, 2024 | -206,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 205,000.00 |
| Mar 31, 2024 | 229,000.00 |
| Dec 31, 2023 | 278,000.00 |
| Sep 30, 2023 | 350,000.00 |
| Jun 30, 2023 | 360,000.00 |
| Mar 31, 2023 | 362,000.00 |
| Dec 31, 2022 | 314,000.00 |
| Sep 30, 2022 | 243,000.00 |
| Jun 30, 2022 | 96,000.00 |
| Mar 31, 2022 | 10,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | 7,000.00 |
| Jun 30, 2021 | -13,000.00 |